查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1527058

全球肉瘤药物市场 2024-2031

Global Sarcoma Drug Market 2024-2031
出版日期: | 出版商: Orion Market Research | 英文 140 Pages | 商品交期: 2-3个工作天内

价格

依治疗类型（化疗、标靶治疗、免疫治疗等）、疾病适应症（软组织肉瘤(STS)、骨肉瘤、胃肠道间质瘤(GIST) 和卡波西氏肉瘤）分類的肉瘤药物市场规模、份额及趋势分析报告）和配销通路（医院药房、零售药房和线上药房）预测期（2024-2031）

肉瘤药物市场预计在预测期内（2024-2031）将以 8.3% 的复合年增长率成长。肉瘤是一种罕见的癌症，发生在骨骼和软组织中，包括脂肪、肌肉、血管、神经、深层皮肤组织和纤维组织。据美国国家癌症研究所称，美国每年诊断出约 12,000 例软组织肉瘤和 3,000 例骨肉瘤。肉瘤的高发生率和盛行率推动了对其治疗方案的需求，从而推动了全球肉瘤药物市场。然而，这些药物的高成本可能会限制市场成长。

目录

第 1 章：报告摘要

  • 目前行业分析及成长潜力展望
  • 研究方法和工具
  • 市场区隔
    • 按细分
    • 按地区

第 2 章：市场概述与见解

  • 报告范围
  • 分析师见解和当前市场趋势
    • 主要市场趋势
    • 建议
    • 结论

第 3 章：竞争格局

  • 主要公司分析
  • Bayer AG
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Eli Lilly and Co.
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • Novartis AG
    • 概述
    • 财务分析
    • SWOT分析
    • 最近的发展
  • 关键策略分析

第 4 章：市场细分

  • 按治疗类型分類的全球肉瘤药物市场
    • 化疗
    • 标靶治疗
    • 免疫治疗
    • 其他（放射治疗）
  • 按疾病适应症分類的全球肉瘤药物市场
    • 软组织肉瘤（STS）
    • 骨肉瘤
    • 胃肠道间质瘤 (GIST)
    • 卡波西氏肉瘤
  • 按配销通路分類的全球肉瘤药物市场
    • 医院药房
    • 零售药房
    • 网路药房

第 5 章：区域分析

  • 北美洲
    • 美国
    • 加拿大
  • 欧洲
    • 英国
    • 德国
    • 义大利
    • 西班牙
    • 法国
    • 欧洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 世界其他地区
    • 拉丁美洲
    • 中东和非洲

第 6 章：公司简介

  • AbbVie Inc.
  • Adaptimmune Ltd.
  • Arcus Biosciences, Inc.
  • AstraZeneca Plc
  • Bristol Myers Squibb Co.
  • Eisai Co., Ltd.
  • F. Hoffmann-La Roche Ltd.
  • Fresenius Kabi AG
  • Gilead Sciences, Inc.
  • GlaxoSmithKline plc.
  • Johnson & Johnson Services, Inc.
  • Merck & Co., Inc.
  • Pfizer Inc.
  • RADIOPHARM THERANOSTICS Ltd.
  • Sanofi S.A.
  • Takeda Pharmaceutical Co. Ltd.
  • Zymeworks BC Inc.
Product Code: OMR2028759

Sarcoma Drug Market Size, Share & Trends Analysis Report by Treatment Type (Chemotherapy, Targeted Therapy, Immuno Therapy, and Others), by Disease Indication (Soft Tissue Sarcoma (STS), Bone Sarcoma, Gastrointestinal Stromal Tumors (GIST), and Kaposi Sarcoma) and by Distribution Channel (Hospital Pharmacy, Retail pharmacy, and Online Pharmacy) Forecast Period (2024-2031)

Sarcoma drug market is anticipated to grow at a CAGR of 8.3% during the forecast period (2024-2031). Sarcomas are rare cancers that develop in the bones and soft tissues, including fat, muscles, blood vessels, nerves, deep skin tissues, and fibrous tissues. According to the National Cancer Institute, about 12,000 cases of soft tissue sarcomas and 3,000 cases of bone sarcomas are diagnosed annually in the US. The high incidence and prevalence of sarcomas has driven the demand for its treatment options thereby driving the global sarcoma drugs market. However, the high cost of these drugs may restrain the market growth.

Market Dynamics

Increasing healthcare expenditure

Healthcare spending, especially in North America, is bolstering the market owing to improved infrastructure and increased awareness of cancer treatments. According to the American Medical Association, in April 2024, health spending in the US rose by 4.1% to reach $4.4 trillion, equivalent to $13,493 per capita. This growth rate is consistent with the rates observed in 2019 before the pandemic. Although government spending to address the pandemic initially caused significant increases in National Health Expenditures (NHE), these expenses declined in 2021, while the utilization of medical goods and services rebounded. By 2022, health spending patterns had largely returned to the pre-pandemic levels.

Increased funding for sarcoma treatment research

The market for sarcoma research and clinical trials is being bolstered by increased funding from both government and private organizations. For instance, in March 2024, Lamassu Bio received a $2.05 million grant from the US National Institutes of Health (NIH) and National Cancer Institute (NCI) for the development of SA53, a new therapeutic for p53 wild-type sarcomas. The funding will advance the progression of the new cancer treatment into clinical trials. Lamassu Bio will carry out the trial in partnership with the Cleveland Clinic Taussig Cancer Center and the Cleveland Clinic Children's Pediatric Hematology and Oncology Department. It will establish a safe dosage of SA53 for future trials.

Market Segmentation

  • Based on treatment type, the market is segmented into chemotherapy, targeted therapy, immunotherapy, and others.
  • Based on disease indication, the market is segmented into soft tissue sarcoma (STS), bone sarcoma, gastrointestinal stromal tumors (GIST), and Kaposi sarcoma.
  • Based on the distribution channel, the market is segmented into hospital pharmacy, retail pharmacy, and online pharmacy.

Gastrointestinal Stromal Tumors (GIST) Sub-segment to Hold a Considerable Market Share

The increasing number of GIST cases and improved diagnostic techniques are leading to higher detection rates and increased demand for effective treatments. According to the US Food and Drug Administration, in May 2020, the FDA approved ripretinib for adult patients with advanced gastrointestinal stromal tumors who have previously received treatment with kinase inhibitors. The drug was evaluated in an international trial, INVICTUS, which included 129 patients who received ripretinib or a placebo until disease progression or unacceptable toxicity. The major efficacy outcome measure was progression-free survival.

Regional Outlook

The sarcoma drug market is further segmented based on geography including North America (the US, and Canada), Europe (UK, Italy, Spain, Germany, France, and the Rest of Europe), Asia-Pacific (India, China, Japan, South Korea, and Rest of Asia-Pacific), and the Rest of the World (the Middle East & Africa, and Latin America).

North America Holds Major Market Share

The increase in sarcoma cases necessitates improved diagnostic techniques and increased awareness for early detection and intervention. According to the American Society of Clinical Oncology (ASCO), in November 2023, it is projected approximately 13,400 new cases of soft-tissue sarcoma in the US, with 7,400 affecting men and boys and 6,000 affecting women and girls. Additionally, it is estimated 5,140 fatalities from this disease, with 2,720 occurring among men and boys and 2,420 among women and girls. The high investment by regional players in the development of sarcoma drugs is further aiding the regional market growth.

Market Players Outlook

The major companies serving the sarcoma drug market include Bayer AG, Eli Lilly and Co., Novartis AG, Merck & Co., Inc., and Pfizer Inc. among others. The market players are increasingly focusing on business expansion and product development by applying strategies such as collaborations, mergers and acquisitions to stay competitive in the market.

Table of Contents

1. Report Summary

  • Current Industry Analysis and Growth Potential Outlook
  • 1.1. Research Methods and Tools
  • 1.2. Market Breakdown
    • 1.2.1. By Segments
    • 1.2.2. By Region

2. Market Overview and Insights

  • 2.1. Scope of the Report
  • 2.2. Analyst Insight & Current Market Trends
    • 2.2.1. Key Market Trends
    • 2.2.2. Recommendations
    • 2.2.3. Conclusion

3. Competitive Landscape

  • 3.1. Key Company Analysis
  • 3.2. Bayer AG
    • 3.2.1. Overview
    • 3.2.2. Financial Analysis
    • 3.2.3. SWOT Analysis
    • 3.2.4. Recent Developments
  • 3.3. Eli Lilly and Co.
    • 3.3.1. Overview
    • 3.3.2. Financial Analysis
    • 3.3.3. SWOT Analysis
    • 3.3.4. Recent Developments
  • 3.4. Novartis AG
    • 3.4.1. Overview
    • 3.4.2. Financial Analysis
    • 3.4.3. SWOT Analysis
    • 3.4.4. Recent Developments
  • 3.5. Key Strategy Analysis

4. Market Segmentation

  • 4.1. Global Sarcoma Drug Market by Treatment Type
    • 4.1.1. Chemotherapy
    • 4.1.2. Targeted Therapy
    • 4.1.3. Immunotherapy
    • 4.1.4. Others (Radiation Therapy)
  • 4.2. Global Sarcoma Drug Market by Disease Indication
    • 4.2.1. Soft Tissue Sarcoma (STS)
    • 4.2.2. Bone Sarcoma
    • 4.2.3. Gastrointestinal Stromal Tumors (GIST)
    • 4.2.4. Kaposi Sarcoma
  • 4.3. Global Sarcoma Drug Market by Distribution Channel
    • 4.3.1. Hospital Pharmacy
    • 4.3.2. Retail Pharmacy
    • 4.3.3. Online Pharmacy

5. Regional Analysis

  • 5.1. North America
    • 5.1.1. United States
    • 5.1.2. Canada
  • 5.2. Europe
    • 5.2.1. UK
    • 5.2.2. Germany
    • 5.2.3. Italy
    • 5.2.4. Spain
    • 5.2.5. France
    • 5.2.6. Rest of Europe
  • 5.3. Asia-Pacific
    • 5.3.1. China
    • 5.3.2. India
    • 5.3.3. Japan
    • 5.3.4. South Korea
    • 5.3.5. Rest of Asia-Pacific
  • 5.4. Rest of the World
    • 5.4.1. Latin America
    • 5.4.2. Middle East and Africa

6. Company Profiles

  • 6.1. AbbVie Inc.
  • 6.2. Adaptimmune Ltd.
  • 6.3. Arcus Biosciences, Inc.
  • 6.4. AstraZeneca Plc
  • 6.5. Bristol Myers Squibb Co.
  • 6.6. Eisai Co., Ltd.
  • 6.7. F. Hoffmann-La Roche Ltd.
  • 6.8. Fresenius Kabi AG
  • 6.9. Gilead Sciences, Inc.
  • 6.10. GlaxoSmithKline plc.
  • 6.11. Johnson & Johnson Services, Inc.
  • 6.12. Merck & Co., Inc.
  • 6.13. Pfizer Inc.
  • 6.14. RADIOPHARM THERANOSTICS Ltd.
  • 6.15. Sanofi S.A.
  • 6.16. Takeda Pharmaceutical Co. Ltd.
  • 6.17. Zymeworks BC Inc.

LIST OF TABLES

  • 1. Global Sarcoma Drug Market Research And Analysis By Treatment Type, 2023-2031 ($ Million)
  • 2. Global Chemotherapy Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 3. Global Targeted Therapy Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 4. Global Immunotherapy Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 5. Global Other Treatment Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 6. Global Sarcoma Drug Market Research And Analysis By Disease Indication 2023-2031 ($ Million)
  • 7. Global Soft Tissue Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 8. Global Bone Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 9. Global Gastrointestinal Stromal Tumors Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 10. Global Kaposi Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 11. Global Sarcoma Drug Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
  • 12. Global Sarcoma Drug For Hospital Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 13. Global Sarcoma Drug For Retail Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 14. Global Sarcoma Drug For Online Pharmacy Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 15. Global Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 16. North American Sarcoma Drug Market Research And Analysis By Country, 2023-2031 ($ Million)
  • 17. North American Saroma Drug Market Research And Analysis By Treatment Type, 2023-2031 ($ Million)
  • 18. North American Sarcoma Drug Market Research And Analysis By Disease Indication, 2023-2031 ($ Million)
  • 19. North American Sarcoma Drug Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
  • 20. European Sarcoma Drug Market Research And Analysis By Country, 2023-2031 ($ Million)
  • 21. European Sarcoma Drug Market Research And Analysis By Treatment Type, 2023-2031 ($ Million)
  • 22. European Sarcoma Drug Market Research And Analysis By Disease Indication, 2023-2031 ($ Million)
  • 23. European Sarcoma Drug Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
  • 24. Asia-Pacific Sarcoma Drug Market Research And Analysis By Country, 2023-2031 ($ Million)
  • 25. Asia-Pacific Sarcoma Drug Market Research And Analysis By Treatment Type, 2023-2031 ($ Million)
  • 26. Asia-Pacific Sarcoma Drug Market Research And Analysis By Disease Indication, 2023-2031 ($ Million)
  • 27. Asia-Pacific Sarcoma Drug Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)
  • 28. Rest Of The World Sarcoma Drug Market Research And Analysis By Region, 2023-2031 ($ Million)
  • 29. Rest Of The World Sarcoma Drug Market Research And Analysis By Treatment Type, 2023-2031 ($ Million)
  • 30. Rest Of The World Sarcoma Drug Market Research And Analysis By Disease Indication, 2023-2031 ($ Million)
  • 31. Rest Of The World Sarcoma Drug Market Research And Analysis By Distribution Channel, 2023-2031 ($ Million)

LIST OF FIGURES

  • 1. Global Sarcoma Drug Market Share By Treatment Type, 2023 Vs 2031 (%)
  • 2. Global Chemotherapy Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 3. Global Targeted Therapy Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 4. Global Immunotherapy Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 5. Global Other Treatment Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 6. Global Sarcoma Drug Market Share By Disease Indication, 2023 Vs 2031 (%)
  • 7. Global Soft Tissue Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 8. Global Bone Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 9. Global Gastrointestinal Stromal Tumors Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 10. Global Kaposi Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 11. Global Sarcoma Drug Market Share By Distribution Channel, 2023 Vs 2031 (%)
  • 12. Global Sarcoma Drug For Online Market Share By Region, 2023 Vs 2031 (%)
  • 13. Global Sarcoma Drug For Offline Market Share By Region, 2023 Vs 2031 (%)
  • 14. Global Sarcoma Drug Market Share By Region, 2023 Vs 2031 (%)
  • 15. US Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 16. Canada Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 17. UK Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 18. France Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 19. Germany Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 20. Italy Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 21. Spain Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 22. Rest Of Europe Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 23. India Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 24. China Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 25. Japan Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 26. South Korea Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 27. Rest Of Asia-Pacific Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 28. Latin America Sarcoma Drug Market Size, 2023-2031 ($ Million)
  • 29. Middle East And Africa Sarcoma Drug Market Size, 2023-2031 ($ Million)